Stars-894

Feature Draft – STARS‑894
Add “Smart Tag Recommendations” to the Content Editor

---

Key results (summary)

• Safety: Gaboxadol was generally well tolerated; most adverse events were mild to moderate. Few discontinuations due to adverse events; one discontinuation for myoclonus reported in the bid arm.
• Efficacy signals: Study was not powered for definitive efficacy, but CGI‑I showed a treatment effect for gaboxadol once daily (qd) with separation from placebo; the bid arm did not show the same separation. Other exploratory measures had variable results.
• Interpretation: Favorable safety profile and a promising signal on global clinician impression for qd dosing, supporting further development; results presented with caveats about statistical power and exploratory nature.

4.1. Scientific Motivation

• Transient High‑Energy Astrophysics: Rapidly evolving phenomena such as short gamma‑ray bursts (GRBs), magnetar giant flares, and tidal disruption events require sub‑second timing and wide‑field coverage.
• Multi‑Messenger Context: Coordinated observations with gravitational‑wave detectors (LIGO/Virgo/KAGRA) and neutrino observatories (IceCube) demand near‑real‑time alerts.
• Technology Gap: Existing missions either lack the required temporal resolution (< 10 ms) or sky coverage (> 1 sr). STARS‑894 addresses both.

9.1. Data Flow

1. Photon Detection – Event packets (time, energy, pixel ID) generated at ≤ 5 µs resolution.
2. On‑board Trigger – Real‑time burst detection; if trigger ≥ 5σ, packet flagged for high‑priority downlink.
3. Buffering – Continuous stream stored in 8 TB SSD (circular buffer, 48 h capacity).
4. Downlink – Ka‑band burst packets transmitted within 30 s; routine science data streamed via X‑band.
5. Ground Reception – DSN stations forward to MOC, then to SDC.

1. Title Page

| Item | Details | |------|----------| | Report Title | STARS‑894: Mission Overview, Technical Assessment, and Preliminary Findings | | Prepared for | [Funding Agency / Stakeholder] | | Prepared by | [Project Team / Department] | | Date | 10 April 2026 | | Confidentiality Level | [Unclassified / Restricted / Confidential] | STARS-894

---

4. Introduction & Background

Publication and registration

• Peer‑reviewed report: "The STARS Phase 2 Study: A Randomized Controlled Trial of Gaboxadol in Angelman Syndrome" — Neurology (2021), DOI: 10.1212/WNL.0000000000011409; full text available on PubMed Central.
• ClinicalTrials.gov: NCT02996305 (study record and details).

6.5 Security & Privacy

• All payloads are transmitted over HTTPS.
• No user‑generated content is stored beyond the short‑term suggestion request (max 5 seconds).
• The NLP service runs in a sandboxed container; no external network access.

9.2. Processing Levels

| Level | Description | |-------|-------------| | Level‑0 | Raw telemetry, time‑ordered, de‑commutated. | | Level‑1 | Calibrated event list (energy correction, gain, dead‑time). | | Level‑2 | Science products – light curves, spectra, sky maps; transient alerts. | | Level‑3 | Derived catalogs (GRB, magnetar, TDE). | Key results (summary)

Processing pipelines are containerized (Docker) and executed on a cloud‑based HPC cluster (NASA CLOUD). Safety: Gaboxadol was generally well tolerated; most adverse